According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “
Several other brokerages have also recently issued reports on EARS. JMP Securities cut shares of Auris Medical Holding AG from an outperform rating to a market perform rating in a research note on Thursday, August 18th. Leerink Swann reaffirmed a buy rating and issued a $12.00 price objective on shares of Auris Medical Holding AG in a research note on Wednesday, June 15th. Jefferies Group reaffirmed a buy rating on shares of Auris Medical Holding AG in a research note on Friday, June 10th. Finally, Needham & Company LLC lifted their price objective on shares of Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a buy rating in a research note on Friday, August 19th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Auris Medical Holding AG presently has an average rating of Buy and an average target price of $8.88.
Shares of Auris Medical Holding AG (NASDAQ:EARS) opened at 1.67 on Thursday. Auris Medical Holding AG has a 52-week low of $1.55 and a 52-week high of $7.96. The firm’s market cap is $57.33 million. The stock has a 50 day moving average of $1.96 and a 200 day moving average of $3.35.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EARS. Advisor Group Inc. purchased a new position in Auris Medical Holding AG during the second quarter valued at $277,000. TFS Capital LLC increased its position in Auris Medical Holding AG by 17.7% in the second quarter. TFS Capital LLC now owns 38,230 shares of the company’s stock valued at $160,000 after buying an additional 5,762 shares during the period. Finally, Bellevue Group AG purchased a new position in Auris Medical Holding AG during the first quarter valued at $7,897,000. 30.95% of the stock is currently owned by institutional investors and hedge funds.
Auris Medical Holding AG Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.